Filtered By:
Condition: Heart Failure
Procedure: Liver Transplant

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 31 results found since Jan 2013.

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Factors associated with major adverse cardiovascular events after liver transplantation among a national sample
This article is protected by copyright. All rights reserved.
Source: American Journal of Transplantation - March 6, 2016 Category: Transplant Surgery Authors: Lisa B. Van Wagner, Marina Serper, Raymond Kang, Josh Levitsky, Samuel Hohmann, Michael Abecassis, Anton Skaro, Donald M. Lloyd‐Jones Tags: Original Article Source Type: research

ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders
This invention involves ApoA-1 mimetic peptides with multiple amphipathic alpha-helical domains that promote lipid efflux from cells and are useful in the treatment and prevention of dyslipidemic, inflammatory and vascular disorders. IND-enabling studies for one of the peptides, named Fx-5A, are completed in preparation for an IND filing at the FDA, to be followed by a Phase I clinical trial planned for 2017. Disorders amenable to treatment with the peptides include hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, HDL deficiency, hypertriglyceridemia, apoA-I deficiency, acute coronary syndrome, angina pectoris, ...
Source: NIH OTT Licensing Opportunities - February 1, 2008 Category: Research Authors: ajoyprabhu3 Source Type: research

Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
Background As mortality from coronavirus disease 2019 (COVID-19) is strongly age-dependent, we aimed to identify population subgroups at an elevated risk for adverse outcomes from COVID-19 using age-/gender-adjusted data from European cohort studies with the aim to identify populations that could potentially benefit from booster vaccinations. Methods We performed a systematic literature review and meta-analysis to investigate the role of underlying medical conditions as prognostic factors for adverse outcomes due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including death, hospitalisation, intensive c...
Source: European Respiratory Review - November 2, 2022 Category: Respiratory Medicine Authors: Vardavas, C. I., Mathioudakis, A. G., Nikitara, K., Stamatelopoulos, K., Georgiopoulos, G., Phalkey, R., Leonardi-Bee, J., Fernandez, E., Carnicer-Pont, D., Vestbo, J., Semenza, J. C., Deogan, C., Suk, J. E., Kramarz, P., Lamb, F., Penttinen, P. Tags: Respiratory infections and tuberculosis Reviews Source Type: research

Stem cells: what happened to the radical breakthroughs?
Much was promised in the late 1990s, but the challenge of advances such as growing whole human organs has been difficult to deliverIt's 1998 and science is taking big strides. The first cloned mammal, Dolly the Sheep, has just had her first lamb; the first robotically assisted heart surgery has been completed; Furbys have hit the shelves. In a bold announcement, biomedical engineer Professor Michael Sefton declared that within 10 years, scientists would have grown an entire heart, fit for transplant. "We're shooting big," he said. "Our vision is that we'll be able to pop out a damaged heart and replace it as easily as you ...
Source: Guardian Unlimited Science - August 10, 2013 Category: Science Authors: Simon Roach Tags: Biology Medical research Features Stem cells The Observer Science Source Type: news

High early cardiovascular mortality following liver transplantation
Abstract Cardiovascular disease (CVD) contributes to excess long‐term mortality after liver transplantation (LT), however little is known about early post‐operative CVD mortality in the current era. In addition, there is no model to predict early post‐operative CVD mortality across centers. We analyzed adult recipients of primary LT in the Organ Procurement and Transplantation Network (OPTN) database between February 2002 and December 2012 to assess prevalence and predictors of early (30‐day) CVD mortality, defined as death from arrhythmia, heart failure, myocardial infarction, cardiac arrest, thromboembolism, and/...
Source: Liver Transplantation - July 5, 2014 Category: Transplant Surgery Authors: Lisa B. VanWagner, Brittany Lapin, Josh Levitsky, John T. Wilkins, Michael M. Abecassis, Anton I. Skaro, Donald M. Lloyd‐Jones Tags: Original Article Source Type: research

High early cardiovascular mortality after liver transplantation
In conclusion, we provide the first multicenter prognostic model for the prediction of early post‐LT CVD death, the most common cause of early post‐LT mortality in the current transplant era. However, evaluations of additional CVD‐related variables not collected by the OPTN are needed in order to improve the model's accuracy and potential clinical utility. Liver Transpl, 2014. © 2014 AASLD.
Source: Liver Transplantation - October 24, 2014 Category: Transplant Surgery Authors: Lisa B. VanWagner, Brittany Lapin, Josh Levitsky, John T. Wilkins, Michael M. Abecassis, Anton I. Skaro, Donald M. Lloyd‐Jones Tags: Original Article Source Type: research

Preexisting Atrial Fibrillation and Cardiac Complications After Liver Transplantation
Conclusion: Although patients with AF have a higher incidence of intraoperative cardiac events, a higher cardiovascular morbidity and a complicated postoperative course, this did not affect overall graft and patient survival. This article is protected by copyright. All rights reserved.
Source: Liver Transplantation - December 8, 2014 Category: Transplant Surgery Authors: Johannes Bargehr, Jorge F. Trejo‐Gutierrez, Tushar Patel, Barry Rosser, Jaime Aranda‐Michel, Maria L. Yataco, C. Burcin Taner Tags: Original Article Source Type: research

“Framingham score, renal dysfunction and cardiovascular risk in liver transplant patients”
Conclusions: In our series, the FRS and eGFR at LT were able to predict the development of post‐LT CV events and poor outcome. This article is protected by copyright. All rights reserved.
Source: Liver Transplantation - March 30, 2015 Category: Transplant Surgery Authors: Tommaso Di Maira, Angel Rubin, Lorena Puchades, Victoria Aguilera, Carmen Vinaixa, Maria Garcia, Nicola De Maria, Erica Villa, Rafael Lopez‐Andujar, Fernando San Juan, Eva Montalva, Judith Perez, Martin Prieto, Marina Berenguer Tags: Original Articles Source Type: research

Impact of Renal Impairment on Cardiovascular Disease Mortality After Liver Transplantation for Nonalcoholic Steatohepatitis Cirrhosis
ConclusionNASH recipients have an increased risk of CVD mortality after liver transplantation explained by a high prevalence of co‐morbid cardiometabolic risk factors that in aggregate identify those at highest risk of post‐transplant CVD mortality.This article is protected by copyright. All rights reserved.
Source: Liver International - May 15, 2015 Category: Gastroenterology Authors: Lisa B. VanWagner, Brittany Lapin, Anton I. Skaro, Donald M. Lloyd‐Jones, Mary E. Rinella Tags: Original Article Source Type: research

Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients
Cardiovascular (CV) events represent major impediments to the long‐term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post‐LT cardiovascular events (CVEs). Patients transplanted between 2006 and 2008 were included. Baseline features, CV risk factors, and CVEs occurring after LT (ischemic heart disease, stroke, heart failure, de novo arrhythmias, and peripheral arterial disease) were recorded. In total, 250 patients (69.6% men) with a median age of 56 years (range, 18‐68 years) were included...
Source: Liver Transplantation - May 26, 2015 Category: Transplant Surgery Authors: Tommaso Di Maira, Angel Rubin, Lorena Puchades, Victoria Aguilera, Carmen Vinaixa, Maria Garcia, Nicola De Maria, Erica Villa, Rafael Lopez‐Andujar, Fernando San Juan, Eva Montalva, Judith Perez, Martin Prieto, Marina Berenguer Tags: Original Article Source Type: research

Frequency of Cardiovascular Events and Effect on Survival in Liver Transplant Recipients for Cirrhosis Due to Alcoholic or Nonalcoholic Steatohepatitis.
CONCLUSIONS: Cardiovascular events occurred with similar frequency in transplant recipients for nonalcoholic steatohepatitis or alcoholic cirrhosis. Patient survival was affected in both groups, but male patients with concomitant hepatitis C virus infection remained at higher risk for a cardiovascular event after liver transplant. Development of a cardiac evaluation protocol for liver transplant recipients could help monitor these patients. PMID: 26581602 [PubMed - as supplied by publisher]
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - November 17, 2015 Category: Transplant Surgery Authors: Piazza NA, Singal AK Tags: Exp Clin Transplant Source Type: research

Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9-Year Experience
Conclusions These data indicate excellent survival for BTT and DT patients on long-term LVAD support. However, for LVAD therapy to become a plausible alternative to heart transplantation, we need to further decrease the incidence of postoperative complications.
Source: The Annals of Thoracic Surgery - May 9, 2016 Category: Cardiovascular & Thoracic Surgery Source Type: research

Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9-Year Experience.
CONCLUSIONS: These data indicate excellent survival for BTT and DT patients on long-term LVAD support. However, for LVAD therapy to become a plausible alternative to heart transplantation, we need to further decrease the incidence of postoperative complications. PMID: 27173072 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - May 9, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Morgan JA, Go PH, Xuereb L, Kaur B, Akrawe S, Nemeh HW, Borgi J, Lanfear DE, Williams CT, Paone G Tags: Ann Thorac Surg Source Type: research